Skip to main content

Table 2 Changes in quality of life from t1 (n = 8) to t2 (n = 8), t3 (n = 8) and t4 (n = 7), ANOVA (standard deviation (±SD), sample size (n), significance value (p), significant (*), highly significant (**), not significant (n.s.) for all p > 0.05) t1, t2, t3, and t4

From: A 1,408 km bicycle tour with prostate cancer patients—results of a pilot study

 

T1

T2

T3

T4

p

EORTC QLQC-30

Quality of life

73.81 ± 8.91

73.81 ± 10.12

82.14 ± 19.50

73.81 ± 13.11

0.447

Physical functioning

98.09 ± 3.25

93.33 ± 5.44

98.10 ± 5.04

95.24 ± 9.97

0.139

Role functioning

95.24 ± 12.60

95.24 ± 12.60

95.24 ± 12.60

88.10 ± 15.85

0.415

Cognitive functioning

80.95 ± 24.40

76.19 ± 28.64

80.95 ± 17.82

90.48 ± 18.90

0.98

Social functioning

85.71 ± 17.82

88.10 ± 15.85

92.86 ± 13.11

83.33 ± 16.67

0.321

Emotional functioning

84.52 ± 18.28

75.00 ± 25.00

90.48 ± 13.11

79.76 ± 24.93

0.097

Fatigue

15.87 ± 24.73

17.46 ± 23.00

9.52 ± 13.50

9.52 ± 13.50

0.246

Nausea/vomiting

0 ± 0

0 ± 0

0 ± 0

0 ± 0

k.A.

Pain

14.29 ± 20.25

4.76 ± 8.13

11.90 ± 20.89

19.05 ± 26.23

0.488

Dyspnea

9.52 ± 25.20

14.29 ± 37.80

0 ± 0

9.52 ± 25.20

0.721

Insomnia

23.81 ± 31.71

33.33 ± 27.22

23.81 ± 25.20

23.81 ± 31.71

0.825

Appetite loss

0 ± 0

0 ± 0

4.76 ± 12.60

0 ± 0

0.415

Constipation

4.76 ± 12.60

4.76 ± 12.60

4.76 ± 12.60

0 ± 0

0.415

Diarrhea

4.76 ± 12.60

4.76 ± 12.60

4.76 ± 12.60

0 ± 0

0.761

Financial difficulties

0 ± 0

0 ± 0

0 ± 0

4.76 ± 12.60

0.415

EORTC PR 25

Sexual functioning

59.52 ± 15.95

61.90 ± 22.55

54.76 ± 22.78

61.90 ± 32.62

0.73

Urinary symptoms

22.88 ± 25.32

25.33 ± 25.95

22.29 ± 23.29

27.38 ± 25.06

0.07

Bowel symptoms

3.57 ± 4.45

2.38 ± 4.06

2.38 ± 4.06

4.76 ± 6.56

0.66

Treatment-related symptoms

19.84 ± 13.90

11.91 ± 16.17

8.41 ± 12.03

13.33 ± 14.55

0.008** (t1–t3: 0.006**)